Interventional Oncology Devices Market to Reach US$ 5.00 Billion by 2033 at 7.1% CAGR; North America Leads with 42% Share | Key Players Medtronic, Boston Scientific, Johnson & Johnson

The Interventional Oncology Devices Market reached US$ 2.70 billion in 2024 and is expected to reach US$ 5.00 billion by 2033, growing at a CAGR of 7.1% during the forecast period 2025-2033. The market is expanding steadily due to the rising global cancer burden and the increasing preference for minimally invasive treatment options that offer reduced recovery time, lower complication risks, and improved patient outcomes.

Growth is driven by the growing adoption of advanced interventional techniques such as tumor ablation, embolization, and image-guided therapies, which are becoming integral to modern oncology care. Continuous technological advancements, including the integration of artificial intelligence, robotics, and enhanced imaging systems, are improving procedural accuracy and treatment efficacy. Increasing clinical acceptance and ongoing innovation in device design continue to support sustained market growth.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/interventional-oncology-devices-market?sai-v

Interventional Oncology Devices Market is the global market for minimally invasive medical devices used to diagnose and treat cancer through image-guided procedures such as ablation, embolization, and biopsy.

Key Developments
✅ January 2026: In the United States, hospitals and cancer centers expanded adoption of minimally invasive interventional oncology devices such as ablation systems, embolization catheters, and image-guided tumor treatment tools to improve patient outcomes and reduce recovery times.

✅ January 2026: In Japan, medical device manufacturers advanced precision-guided interventional oncology technologies, including microwave and radiofrequency ablation systems, to support treatment of liver, lung, and kidney cancers.

✅ January 2026: In Europe, growing preference for image-guided and catheter-based cancer therapies drove increased use of interventional oncology devices in combination with chemotherapy and immunotherapy protocols.

✅ December 2025: In the United States, integration of interventional oncology devices with advanced imaging, navigation software, and robotic assistance enhanced procedural accuracy and expanded clinical indications.

✅ December 2025: In Japan, clinical collaborations between hospitals and device companies supported evaluation of next-generation embolization materials and drug-eluting technologies.

✅ December 2025: In Asia-Pacific, rising cancer prevalence and expanding access to advanced oncology care accelerated demand for cost-effective and minimally invasive interventional oncology solutions.

Mergers & Acquisitions
✅ January 2026: In the United States, a leading medical device company acquired an interventional oncology technology firm to strengthen its portfolio in tumor ablation and image-guided cancer therapies.

✅ December 2025: In the United States, a healthcare technology group completed the acquisition of a catheter-based oncology device manufacturer to expand offerings in minimally invasive cancer treatment.

✅ December 2025: In Japan, a diversified medical device company increased its stake in an interventional oncology startup focused on advanced embolization and targeted delivery systems.

✅ August 2025: In Europe, a specialty medical device manufacturer acquired a regional interventional oncology solutions provider to enhance its presence in hospital-based cancer care markets.

Key Players
Medtronic | Boston Scientific | BD | Terumo | Merit Medical | AngioDynamics | Johnson & Johnson | Teleflex | Cook Medical | HealthTronics | Others

Key Highlights
Medtronic holds 22.5% share, driven by its broad interventional and minimally invasive device portfolio, strong clinical outcomes, and global hospital penetration.

Boston Scientific holds 19.1% share, supported by continuous innovation in vascular and interventional technologies and strong adoption across cardiology and oncology procedures.

Johnson & Johnson holds 15.4% share, leveraging diversified medical device offerings, strong brand trust, and extensive global distribution networks.

BD holds 12.8% share, driven by leadership in vascular access devices, interventional tools, and strong presence in hospital-based care settings.

Terumo holds 9.6% share, supported by advanced catheter technologies, strong R&D focus, and growing footprint in cardiovascular and endovascular applications.

Teleflex holds 7.4% share, focused on minimally invasive medical technologies, specialty catheters, and procedural solutions.

Cook Medical holds 6.1% share, driven by physician-led innovation, niche interventional products, and strong clinical collaboration model.

Merit Medical holds 4.2% share, supported by cost-effective interventional devices and expanding product lines across vascular procedures.

AngioDynamics holds 2.8% share, focused on vascular access, oncology support devices, and minimally invasive treatment solutions.

HealthTronics holds 1.1% share, driven by specialized urology and vascular treatment technologies and service-based offerings.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=interventional-oncology-devices-market?sai-v

Market Drivers
- Rising global incidence of cancer and increasing preference for minimally invasive treatment options.

- Growing adoption of image-guided procedures for precise tumor targeting and reduced damage to healthy tissues.

- Increasing demand for localized cancer therapies with shorter hospital stays and faster patient recovery.

- Advancements in imaging technologies and interventional radiology improving procedural accuracy and outcomes.

- Expansion of healthcare infrastructure and oncology services in emerging economies.

Industry Developments
- Development of advanced ablation devices including radiofrequency, microwave, cryoablation, and irreversible electroporation systems.

- Integration of real-time imaging, navigation, and robotic assistance in interventional oncology procedures.

- Strategic partnerships between medical device manufacturers, hospitals, and research institutions.

- Increasing clinical adoption of combination therapies integrating interventional oncology with systemic treatments.

- Rising investments in R&D and clinical trials for next-generation minimally invasive oncology devices.

Regional Insights
North America - 42% share: "Driven by high cancer prevalence, advanced interventional radiology infrastructure, early adoption of innovative devices, and favorable reimbursement policies."

Europe - 28% share: "Supported by well-established healthcare systems, strong clinical research activity, and increasing adoption of minimally invasive oncology procedures."

Asia Pacific - 23% share: "Fueled by growing cancer burden, improving access to advanced medical devices, and expanding interventional radiology capabilities."

Latin America - 5% share: "Driven by gradual modernization of oncology care, increasing awareness of minimally invasive treatments, and expanding hospital infrastructure."

Middle East & Africa - 2% share: "Supported by investments in advanced healthcare facilities, growing oncology services, and rising adoption of image-guided interventions."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/interventional-oncology-devices-market?sai-v

Key Segments

By Product Type
Ablation devices dominate the market, driven by their minimally invasive nature and effectiveness in destroying tumors. Embolization devices hold a significant share, supported by increasing use in targeted tumor therapy and palliative care. Biopsy devices account for a notable segment, driven by rising demand for image-guided tissue sampling. Support devices, including catheters, guidewires, and imaging accessories, contribute steadily by enabling precise interventional procedures.

By Procedure
Tumor ablation represents a major segment, driven by adoption of radiofrequency, microwave, and cryoablation techniques. Transarterial chemoembolization and radioembolization account for a significant share, supported by effectiveness in treating unresectable tumors. Image-guided biopsy procedures continue to grow, driven by early cancer diagnosis and treatment planning. Other procedures include venous access, pain management, and combined interventional therapies.

By Cancer Type
Liver cancer dominates the market, driven by high prevalence and strong adoption of interventional therapies. Lung cancer represents a significant segment, supported by growing use of minimally invasive ablation techniques. Kidney cancer adoption is increasing steadily, driven by nephron-sparing treatment approaches. Breast cancer contributes through image-guided interventions and localized therapies. Other cancer types include prostate, bone, and pancreatic cancers.

By End User
Hospitals represent the largest end-user segment, driven by availability of advanced imaging infrastructure and skilled interventional radiology teams. Specialty cancer centers hold a substantial share, supported by focused oncology expertise and high procedure volumes. Ambulatory surgical centers are growing steadily, driven by minimally invasive procedures and shorter recovery times.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.